US equities |
NVDA $184.23 ▼-7.94% MU $714.20 ▼-10.19% TSLA $347.04 ▼-9.90% SPCX $122.99 ▼-9.51% AAPL $347.66 ▼-0.53% AMZN $255.81 ▼-3.84% AMD $429.35 ▼-12.16% SNDK $884.84 ▼-14.71%
FinancialContent

Geron Corporation - Common Stock (NQ:GERN)

0.9911 -0.0889 (-8.23%)
Delayed Quote Updated: 10:45 AM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Geron Corporation - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS
From Geron Corporation
Via Business Wire
News headline image
Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients
From Geron Corporation
Via Business Wire
News headline image
Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
From Geron Corporation
Via Business Wire
News headline image
Geron (GERN) Q1 2023 Earnings Call Transcript ↗
GERN earnings call for the period ending March 31, 2023. 
Via The Motley Fool
News headline image
Recap: Geron Q1 Earnings ↗
 
Via Benzinga
News headline image
A Preview Of Geron's Earnings ↗
 
Via Benzinga
News headline image
Looking Into Geron's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Geron to Host Virtual Investor Event on June 14, 2023
From Geron Corporation
Via Business Wire
News headline image
Market Mixes It Up With A Broad Rally ↗
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
Via Talk Markets
News headline image
Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients
From Geron Corporation
Via Business Wire
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
The Latest Analyst Ratings for Geron ↗
 
Via Benzinga
News headline image
Geron (GERN) Q4 2022 Earnings Call Transcript ↗
GERN earnings call for the period ending December 31, 2022. 
Via The Motley Fool
News headline image
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Onfolio Holdings, Inc. (NASDAQ: ONFO) gained 73% to $2.02 after the company announced it completed development of a generative AI search tool. 
Via Benzinga
News headline image
Booz Allen Hamilton, Workday, Marvell Technology And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Earnings Outlook For Geron ↗
 
Via Benzinga
News headline image
Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
From Geron Corporation
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
News headline image
Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
From Geron Corporation
Via Business Wire
News headline image
Geron Corporation Reports First Quarter 2023 Financial Results and Business Highlights
From Geron Corporation
Via Business Wire
News headline image
Geron to Announce First Quarter 2023 Financial Results on May 11, 2023
From Geron Corporation
Via Business Wire
News headline image
Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial
From Geron Corporation
Via Business Wire
News headline image
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
News headline image
Why Shares of Geron Are Up 30% This Week ↗
The company's CEO was scheduled to speak at a virtual conference on Thursday. 
Via The Motley Fool
News headline image
Geron to Present at Upcoming Investor Conferences in April
From Geron Corporation
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023 ↗
 
Via Benzinga
News headline image
7 Biotech Stocks Sitting in the Sweet Spot ↗
Biotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable. 
Via InvestorPlace
News headline image
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
News headline image
Geron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones
From Geron Corporation
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >